Wall Street brokerages expect that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will post earnings per share (EPS) of ($0.10) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings per share of ($0.09) during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.1%. The company is expected to report its next quarterly earnings report on Monday, November 13th.

On average, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.38) per share for the current financial year. For the next year, analysts expect that the firm will post earnings of ($0.42) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.04.

Several brokerages have recently issued reports on BCLI. Maxim Group set a $9.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 16th. ValuEngine upgraded Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 22nd.

Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up 1.46% on Friday, reaching $4.17. 17,841 shares of the company traded hands. The stock’s market capitalization is $78.24 million. The firm has a 50 day moving average price of $4.25 and a 200 day moving average price of $4.20. Brainstorm Cell Therapeutics has a 52-week low of $2.06 and a 52-week high of $5.18.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sphera Funds Management LTD. acquired a new stake in Brainstorm Cell Therapeutics in the 2nd quarter worth approximately $2,759,000. Vanguard Group Inc. lifted its holdings in Brainstorm Cell Therapeutics by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after purchasing an additional 17,657 shares during the last quarter. Finally, KCG Holdings Inc. lifted its holdings in Brainstorm Cell Therapeutics by 4.6% in the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 1,820 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) Will Announce Earnings of -$0.10 Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/16/analysts-expect-brainstorm-cell-therapeutics-inc-bcli-will-announce-earnings-of-0-10-per-share.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.